Assessment of specific human antibodies against SARS-CoV-2 receptor binding domain by rapid in-house ELISA

• Published in: Human antibodies Vol. 30; no. 2; p. 105
• Main Authors: Hussein, Nahla A, Ali, Esraa A A, El-Hakim, Amr E, Tabll, Ashraf A, El-Shershaby, Asmaa, Salamony, Azza, Shaheen, Mohamed N F, Ali, Ibrahim, Elshall, Mahmoud, Shahein, Yasser E
• Format: Journal Article
• Language: English
• Published: Netherlands 2022
• Subjects: COVID-19; SARS-CoV-2; human sera; RBD; diagnosis; ELISA
• ISSN: 1875-869X

The recently emerged SARS-CoV-2 caused a global pandemic since the last two years. The urgent need to control the spread of the virus and rapid application of the suitable health measures raised the importance of available, rapid, and accurate diagnostic approaches. The purpose of this study is to describe a rapid in-house optimized ELISA based on the expression of the receptor binding domain (RBD) of the SARS-CoV-2 spike protein in a prokaryotic system. We show the expression of the 30 kDa recombinant SARS-CoV-2 RBD-6×His in four different E. coli strains (at 28∘C using 0.25mM IPTG) including the expression strain E. coli BL21 (DE3) Rosetta Gami. SARS-CoV-2 rRBD-6×His protein was purified, refolded, and used as an antigen coat to assess antibody response in human sera against SARS-CoV-2 infection. The assessment was carried out using a total of 155 human sero-positive and negative SARS-CoV-2 antibodies. The ELISA showed 69.5% sensitivity, 88% specificity, 78.5% agreement, a positive predictive value (PPV) of 92.3%, and a negative predictive value of 56.5%. Moreover, the optical density (OD) values of positive samples significantly correlated with the commercial kit titers. Specific human antibodies against SARS-CoV-2 spike protein were detected by rapid in-house ELISA in sera of human COVID-19-infected patients. The availability of this in-house ELISA protocol would be valuable for various diagnostic and epidemiological applications, particularly in developing countries. Future studies are planned for the use of the generated SARS-CoV-2 rRBD-6×His protein in vaccine development and other diagnostic applications.